The latest first-in-human trial initiations include projects licensed in by Gilead and Context.
ApexOnco Front Page
Recent articles
In ALK-positive NSCLC Nuvalent is starting a first-line phase 3, but the ROS1 path could be easier.
The latest B7-H4 ADC shows activity only in biomarker-positive patients.
But the timeline for a US green light is less clear, and the group has a cash crisis.
First-in-human trial initiations include Biocytogen's DM002 and Day One's DAY301.
An anti-integrin β6 ADC and a CDK4 inhibitor shoot for bigger markets.
The private group taps DualityBio for an EGFR x HER3 ADC.
Galapagos distances itself from Gilead, and offers a pure-play oncology cell therapy focus.
